The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responses
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
We investigated the in vivo function of the B7 family member B7-H3 (also known as B7RP-2) by gene targeting. B7-H3 inhibited T cell proliferation mediated by antibody to T cell receptor or allogeneic antigen-presenting cells. B7-H3-deficient mice developed more severe airway inflammation than did wild-type mice in conditions in which T helper cells differentiated toward type 1 (T(H)1) rather than type 2 (T(H)2). B7-H3 expression was consistently enhanced by interferon-gamma but suppressed by interleukin 4 in dendritic cells. B7-H3-deficient mice developed experimental autoimmune encephalomyelitis several days earlier than their wild-type littermates, and accumulated higher concentrations of autoantibodies to DNA. Thus, B7-H3 is a negative regulator that preferentially affects T(H)1 responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, CD276 (B7-H3), known to augment Tregs and inhibit T cell responses (Costa et al., 2018, Prasad et al., 2004, Suh et al., 2003), was expressed most prominently on CAFs and TSKs.”
From Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma (2020) · cites this paper as Suh et al., 2003
In the citing paper
“B7H3 has been shown to promote tumor metastasis and invasion via suppression of both CD8+ and CD4 + T cell proliferation and activity86,87.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [87]
Citations
Cites
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., & Steinman, R. M. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.6.1693 · Cited by 3,738
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Self-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · cited 1×
“The idea that PD-1 has an immune inhibitory function is supported by the phenotype of PD-1-deficient mice, which develop lupus-like diseases or autoimmune dilated cardiomyopath”
BackgroundCD28/B7 SYSTEM OF T CELL COSTIMULATION
Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.233 · Cited by 2,717 · cited 1×
“gif" NDATA ITEM> ]> An optimal T cell response is achieved by a combination of signals delivered through the antigen-specific T cell receptor (TCR) and accessory signals that are either stimulatory or inhibitor”
BackgroundDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Cited by
Items 201–300 of 573
Zhang, J., Wang, J., Marzese, D. M., Wang, X., Yang, Z., Li, C., Zhang, H., Zhang, J., Chen, C. C., Kelly, D. F., et al. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0238-5 · Cited by 56
You, G., Lee, Y., Kang, Y., Park, H. W., Park, K., Kim, H., Kim, Y., Kim, S., Kim, J., Moon, D., et al. (2021) · Science Advances · doi:10.1126/sciadv.aax3160 · Cited by 59
“B7-H3 is believed to be a coinhibitory receptor in the B7-CD28 pathway (50, 51), and the interaction with an as-yet-unidentified ligand decreases the proliferation and cytokine production of T cells (52).”
BackgroundThe CD28–B7 Family of Co-signaling Molecules
Nagai, S., & Azuma, M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_2 · Cited by 61
Tumor Microenvironment and Hydrogel-Based 3D Cancer Models for In Vitro Testing Immunotherapies
Vitale, C., Marzagalli, M., Scaglione, S., Dondero, A., Bottino, C., & Castriconi, R. (2022) · Cancers · doi:10.3390/cancers14041013 · Cited by 62
B7-H3 in Brain Malignancies: Immunology and Immunotherapy
Guo, X., Chang, M., Wang, Y., Xing, B., & Ma, W. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.85813 · Cited by 58
“Studies have demonstrated that B7-H3 inhibits cytokine production through signaling pathways involving NFTA, NF-kappaB, and AP-1 factors, which regulate gene transcription and immune cell proliferation [66-68].”
BackgroundKatayama (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.949 · Cited by 55
Immune barriers to successful gene therapy
Wu, T.-L., & Ertl, H. C. J. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.11.005 · Cited by 57
Caliman, E., Fancelli, S., Petroni, G., Michelet, M. R. G., Cosso, F., Ottanelli, C., Mazzoni, F., Voltolini, L., Pillozzi, S., & Antonuzzo, L. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.11.014 · Cited by 66
An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers
Zekri, L., Lutz, M. S., Prakash, N., Manz, T., Klimovich, B., Mueller, S., Hoerner, S., Hagelstein, I., Engel, M., Chashchina, A. A., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.02.010 · Cited by 58
Nanomedicine in Lung Cancer Immunotherapy
Doroudian, M., Zanganeh, S., Abbasgholinejad, E., & Donnelly, S. C. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1144653 · Cited by 55
“A great range of immune checkpoint molecules, such as PD-1 (Okazaki and Honjo, 2007), PD-L1 (Herbst et al., 2014), CD73 (Allard et al., 2017), Lag-3 (Andrews et al., 2017), B7H3 (Suh et al., 2003), TIM-3 (Anderson et al., 2016), CTLA-4 (Krummel and Allison, 1995), TIGIT (Kurtulus et al., 2015), and VISTA (Wang et al.,…”
Roadmap to a Better Therapeutic Tumor Vaccine
Emens, L. A. (2006) · International Reviews of Immunology · doi:10.1080/08830180600992423 · Cited by 61
Zhang, G., Huang, H., Zhu, Y., Yu, G., Gao, X., Xu, Y., Liu, C., Hou, J., & Zhang, X. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.977164 · Cited by 58
“B7-H3 deficient mice develop severe EAE and airway inflammation.(15) In human cancer, B7-H3 is detected on tumor cells arising from diverse tissues, and the expression level of B7-H3 is associated with increased disease severity.”
BackgroundT cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics
Barach, Y. S., Lee, J. S., & Zang, X. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.09.006 · Cited by 59
LAG3 (CD223) and autoimmunity: Emerging evidence
Hu, S., Liu, X., Li, T., Li, Z., & Hu, F. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102504 · Cited by 58
Costimulation blockade and its possible future use in clinical transplantation
Snanoudj, R., Preneuf, H. D., Créput, C., Arzouk, N., Deroure, B., Beaudreuil, S., Dürrbach, A., & Charpentier, B. (2006) · Transplant International · doi:10.1111/j.1432-2277.2006.00332.x · Cited by 54
“However, the recently characterized B7-H3 mouse was shown to develop more severe autoimmune conditions than wild-type mice suggesting that B7-H3 may also suppress T-cell activation and functions [69].”
BackgroundRetroviral and Lentiviral Vectors for the Induction of Immunological Tolerance
Dufait, I., Liechtenstein, T., Lanna, A., Bricogne, C., Laranga, R., Padella, A., Breckpot, K., & Escors, D. (2012) · Scientifica · doi:10.6064/2012/694137 · Cited by 66
Fauci, J. M., Sabbatino, F., Wang, Y., Londoño-Joshi, A. I., Straughn, J. M., Landen, C. N., Ferrone, S., & Buchsbaum, D. J. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.10.038 · Cited by 55
“B7-H3 is a member of the B7superfamily of ligands, and is believed to play a role in down-regulation of T-cells involved in tumor immunity [17,18].”
BackgroundRoles of coinhibitory molecules B7-H3 and B7-H4 in esophageal squamous cell carcinoma
Ling, W., Cao, N., Wang, S., Man, H., Li, P.-F., & Shan, B.-E. (2015) · Tumor Biology · doi:10.1007/s13277-015-4132-5 · Cited by 55
“However, B7-H3 can be induced on certain types of activated immune cells’ surface [10].”
Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors
Almahmoud, S. A., & Zhong, H. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184654 · Cited by 55
Master switches of T-cell activation and differentiation
Beier, K. C., Kallinich, T., & Hamelmann, E. H. (2007) · European Respiratory Journal · doi:10.1183/09031936.00094506 · Cited by 64
“However, analysis of B7-H3-deficient mice indicated an inhibitory effect on T-cell function [ 44 ].”
BackgroundPD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation
del Rio, M., Bühler, L. H., Gibbons, C., Tian, J., & Rodríguez-Barbosa, J.-I. (2008) · Transplant International · doi:10.1111/j.1432-2277.2008.00726.x · Cited by 57
“Overall, these facts point out that, at least in vitro, B7-H3 is involved in the delivery of negative signals to murine T cells [95].”
Background4IgB7‐H3 is the major isoform expressed on immunocytes as well as malignant cells
Zhou, Y., Chen, Y. ‐., Ma, Z., Xu, L., Wang, Q., Zhang, G. ‐., Xie, F., Ge, Y., Wang, X., & Zhang, X. (2007) · Tissue Antigens · doi:10.1111/j.1399-0039.2007.00853.x · Cited by 50
Immune checkpoint molecules in acute myeloid leukaemia: managing the double‐edged sword
Hobo, W. A., Hutten, T. J. A., Schaap, N. P., & Dolstra, H. (2018) · British Journal of Haematology · doi:10.1111/bjh.15078 · Cited by 58
Grabmeier‐Pfistershammer, K., Klauser, C., Pickl, W. F., Stöckl, J., Leitner, J. M., Zlabinger, G. J., Majdic, O., & Steinberger, P. (2006) · European Journal of Immunology · doi:10.1002/eji.200535344 · Cited by 50
B7-H3 silencing by RNAi inhibits tumor progression and enhances chemosensitivity in U937 cells
Zhang, W., Wang, J., Wang, Y., Dong, F., Zhu, M., Wan, W., Li, H.-S., Wu, F., Yan, X., & Ke, X. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s85272 · Cited by 52
Trophoblast Immune Receptors in Maternal-Fetal Tolerance
Riley, J. K. (2008) · Immunological Investigations · doi:10.1080/08820130802206066 · Cited by 55
“Studies conducted using human T cells and B7-H3 deficient mice suggest B7-H3 is a negative regulator of T cell responses (Ling et al., 2003; Suh et al., 2003).”
MethodB7-H3 regulates the development of experimental allergic conjunctivitis in mice
Fukushima, A., Sumi, T., Fukuda, K., Kumagai, N., Nishida, T., Yamazaki, T., Akiba, H., Okumura, K., Yagita∥, H., & Ueno, H. (2007) · Immunology Letters · doi:10.1016/j.imlet.2007.07.011 · Cited by 49
B7-H3 was Highly Expressed in Human Primary Hepatocellular Carcinoma and Promoted Tumor Progression
Wang, F., Wang, G., Liu, T., Yu, G., Zhang, G., & Luan, X. (2014) · Cancer Investigation · doi:10.3109/07357907.2014.909826 · Cited by 50
“Both 2IgB7-H3 and the 4IgB7-H3 fusion protein can inhibit the proliferation of CD4+ T cells in vitro as well as downregulate the secretion of IFN-γ , IL-2, IL-6, IL-8, and IL-10 from T cells (10); because of these findings, B7-H3 was identified as a negative regulatory molecule.”
BackgroundInfluentialB7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma
Lu, Z., Zhao, Z., Cheng, P., Huang, F., Guan, X., Zhang, M., Chen, H., Liu, Z., Jiang, Z., Zheng, Z., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-0587-z · Cited by 53
“Several studies have found that B7-H3 mainly has an inhibitory function in tumor sites and creates an immunosuppressive microenvironment with other immune checkpoints [45].”
BackgroundCo‐stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily
Peggs, K. S., & Allison, J. P. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05627.x · Cited by 60
“The phenotype of B7-H3-deficient mice supports an inhibitory role, with enhanced severity of pathology under Th1-polarising conditions in airway inflammation experiments coupled with increased T cell responses (Suh et al, 2003).”
BackgroundImmune checkpoint: The novel target for antitumor therapy
Jiang, X., Liu, G., Li, Y., & Pan, Y. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.12.004 · Cited by 54
“Hence, B7-H3 expressed on T cells, NK cells and APC has a dual role, it is a negative regulator of adaptive immune responses with a partial co-stimulation.(92) Xingxing Zang’s study showed that strong B7-H3 expression on prostate cancer tumor cells is associated with an increased risk of clinical cancer recurrence and…”
BackgroundInamura, K., Amori, G., Yuasa, T., Yamamoto, S., Yonese, J., & Ishikawa, Y. (2019) · Cancer Management and Research · doi:10.2147/cmar.s209205 · Cited by 47
“While physiological functions of B7-H3 remain elusive, B7-H3 is highly expressed in the tumor vessels of renal, lung, colon, breast, endometrial, and ovarian cancers, but not in the blood vessels of their corresponding normal tissues.14,15,29,31 In RCC, anti-B7-H3 therapy may simultaneously target both the tumor and s…”
BackgroundModulating Co-Stimulation During Antigen Presentation to Enhance Cancer Immunotherapy
Liechtenstein, T., Dufait, I., Lanna, A., Breckpot, K., & Escors, D. (2012) · Immunology Endocrine & Metabolic Agents - Medicinal Chemistry · doi:10.2174/187152212802001875 · Cited by 58
“B7-H3 is preferentially a negative regulator of T cell responses that is expressed by a wide range of cells including DC, monocytes [134-137], T cells [138] and tumour cells [139, 140].”
BackgroundAberrant expression of B7-H3 in gastric adenocarcinoma promotes cancer cell metastasis
Dai, W., Shen, G., Qiu, J., Zhao, X., & Gao, Q. (2014) · Oncology Reports · doi:10.3892/or.2014.3405 · Cited by 46
“Previous studies found that B7-H3deficient mice showed airway inflammation (10), experimental autoimmune encephalitis (11) and allergic conjunctivitis in an accelerated pattern (12).”
BackgroundRetractedB7-H3 and B7-H4 are independent predictors of a poor prognosis in patients with pancreatic cancer
Xu, H., Chen, X., Tao, M., CHEN, K., CHEN, C., Xu, G., Li, W., YUAN, S., & Mao, Y. (2016) · Oncology Letters · doi:10.3892/ol.2016.4128 · Cited by 49
“The stimulatory properties of B7-H3 consist of promoting T cell proliferation and interferon-γ production (10), while the inhibitory properties consist of impairing type 1 T-helper cell responses and protecting cells from natural killer cell-mediated lysis (11).”
T lymphocyte-targeted immune checkpoint modulation in glioma
Kelly, W., Giles, A. J., & Gilbert, M. R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000379 · Cited by 51
Kobori, H., Hashiguchi, M., Piao, J., Kato, M., Ritprajak, P., & Azuma, M. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03236.x · Cited by 49
Chen, X., Quinn, E. M., Ni, H., Wang, J., Blankson, S., Redmond, H. P., Wang, J. H., & Feng, X. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103715 · Cited by 48
Sun, J., Fu, F., Gu, W., Yan, R., Zhang, G., Shen, Z., Zhou, Y., Wang, H., Shen, B., & Zhang, X. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024751 · Cited by 44
“Although there were a few literatures reporting on an inhibitory role of murine B7-H3 (mB7-H3) [10,11], a great quantity of literatures stated that mB7-H3 acted as a positive costimulatory molecule for T cell [5–8,12–16].”
BackgroundBTNL8, a butyrophilin-like molecule that costimulates the primary immune response
Chapoval, A. I., Smithson, G. M., Brunick, L., Mesri, M., Boldog, F. L., Andrew, D. P., Khramtsov, N. V., Feshchenko, E. A., Starling, G. C., & Mézeš, P. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.08.003 · Cited by 48
“T cells results in activation of T lymphocytes (Chapoval et al., 2001; Luo et al., 2004), whereas B7-H3 knockout mice show augmented T cell responses, suggesting an inhibitory function (Suh et al., 2003).”
BackgroundB7-H3 and its relevance in cancer immunological and non-immunological perspectives
Nygren, M. K. (2011) · Frontiers in Bioscience-Elite · doi:10.2741/e304 · Cited by 43
Costimulation blockade: towards clinical application
Timothy, A. W. (2007) · Frontiers in bioscience · doi:10.2741/2829 · Cited by 47
“Additional, studies cumulatively support an ambiguous role, showing both positive and negative costimulatory contributions to immune response (196-199).”
BackgroundMicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer
Wang, Z., Zhong, M., Bian, Y., Mu, Y., Qin, S., Yu, M., & Qin, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10023 · Cited by 41
The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer
Xu, P., Wasielewski, L. J., Yang, J. C., Cai, D., Evans, C. P., Murphy, W. J., & Liu, C. (2022) · Biomedicines · doi:10.3390/biomedicines10081778 · Cited by 46
“As a co-stimulatory molecule, it assists in T-cell activation and interferon gamma (IFN-γ) production [90], and conversely, it also inhibits the proliferation of CD4+ and CD8+ T cells [91].”
BackgroundBlocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview
Alme, A., Karir, B. S., Faltas, B. M., & Drake, C. G. (2016) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.01.006 · Cited by 45
“Later work suggested that ligation of B7-H3 could mediate suppression of TH1 responses [90].”
BackgroundLi, Y., Zhang, J., Han, S., Qian, Q., Chen, Q., Liu, L., & Zhang, Y. (2017) · Oncology Reports · doi:10.3892/or.2017.5730 · Cited by 41
Aung, P. P., Parra, E. R., Barua, S., Sui, D., Ning, J., Mino, B., Ledesma, D. A., Curry, J. L., Nagarajan, P., Torres-Cabala, C. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2355 · Cited by 44
“B7-H3 is a recently identified member of the B7/CD28 superfamily and, in most contexts, functions through an unknown receptor to inhibit T-cell proliferation (46) and dampen type 1 T-helper cell responses (47).”
BackgroundPotential Therapeutic Targets of B7 Family in Colorectal Cancer
Wang, C., Feng, H., Cheng, X., Liu, K., Cai, D., & Zhao, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00681 · Cited by 43
“B7-H3 signal blockade augmented the responses of TH1 cells, but not TH2 cells or antiviral cytotoxic T lymphocytes (CTLs) (21).”
BackgroundParker, A. S., Heckman, M. G., Sheinin, Y. M., Wu, K. J., Hilton, T. W., Diehl, N. N., Pisansky, T. M., Schild, S. E., Kwon, E. D., & Buskirk, S. J. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.01.061 · Cited by 39
Blockade of the B7-H1/PD-1 Pathway as a Basis for Combination Anticancer Therapy
Sznol, M. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000056 · Cited by 41
Kreymborg, K., Haak, S., Murali, R., Wei, J., Waitz, R., Gasteiger, G., Savage, P. A., van den Brink, M. R. M., & Allison, J. P. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0100 · Cited by 43
“Furthermore, the receptor(s) for B7-H3 or B7-H4 have not been identified conclusively, and the physiologic role of B7-H3 particularly is elusive, as both immune-stimulatory and immune-inhibitory capacities have been demonstrated in vitro and in vivo (6;7).”
BackgroundXu, Y., Zhang, G., Wang, J., & Hua-cheng, H. (2010) · Saudi Medical Journal · doi:10.15537/1658-3175.5114 · Cited by 42
Profiling targetable immune checkpoints in osteosarcoma
McEachron, T. A., Triche, T. J., Sorenson, L., Parham, D. M., & Carpten, J. D. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1475873 · Cited by 44
Kim, N. I., Park, M. H., Kweon, S., & Lee, J. S. (2020) · Pathobiology · doi:10.1159/000505756 · Cited by 43
Xuan, Y., Sheng, Y., Zhang, D., Zhang, K., Zhang, Z., Yü, P., Wang, S., Shi, X., Lian, J., Liu, K., et al. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101138 · Cited by 42
Lechmann, M., Shuman, N., Wakeham, A. C., & Mak, T. W. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806335105 · Cited by 39
Self-citationThe novel non‐immunological role and underlying mechanisms of B7‐H3 in tumorigenesis
Zhou, X., Ouyang, S., Li, J., Huang, X., Ai, X., Zeng, Y., Lv, Y.-C., & Cai, M. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28936 · Cited by 41
“Suh et al. (2003) showed that B7‐H3 protein is only expressed in dendritic cells, inactivated T cell (T‐lymphocyte), or macrophages.”
BackgroundZhang, G. ‐., Zhou, H., Chen, Y. ‐., Ge, Y., Xie, F., Shi, Q., Ma, H., Fei, M., & Zhang, X. (2005) · Tissue Antigens · doi:10.1111/j.1399-0039.2005.00449.x · Cited by 37
Ueno, T., Yeung, M. Y., McGrath, M. M., Yang, S., Zaman, N., Snawder, B., Padera, R. F., Magee, C. N., Gorbatov, R., Hashiguchi, M., et al. (2012) · European Journal of Immunology · doi:10.1002/eji.201242501 · Cited by 37
Introduction to Costimulation and Costimulatory Molecules
Mir, M. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-802585-7.00001-7 · Cited by 59
Update of early phase clinical trials in cancer immunotherapy
Lee, D. H. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.242 · Cited by 41
Tyagi, A., Ly, S., El-Dana, F., Yuan, B., Jaggupilli, A., Grimm, S., Konopleva, M. Y., Bühring, H., & Battula, V. L. (2022) · Blood · doi:10.1182/blood.2021014671 · Cited by 37
Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
Kuske, M., Haist, M., Jung, T., Grabbe, S., & Bros, M. (2022) · Cancers · doi:10.3390/cancers14071710 · Cited by 39
Switchable CAR T cell strategy against osteosarcoma
Hidalgo, L., Somovilla-Crespo, B., Garcia-Rodriguez, P., Morales‐Molina, Á., Rodríguez-Milla, M. Á., & García-Castro, J. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03437-z · Cited by 41
“Member of B7 family, B7-H3 acts as an immune checkpoint protein inhibiting the function of T cells [18, 19].”
BackgroundPitts, S. C., Schlom, J., & Donahue, R. N. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03074-z · Cited by 39
Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
dos Santos, L. V., Abrahão, C. M., & William, W. N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.596290 · Cited by 42
Emerging immunotherapies for bladder cancer
Kim, J. W., Tomita, Y., Trepel, J. B., & Apolo, A. B. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000177 · Cited by 36
“In a murine model, B7H3-deficient mice developed increased T helper type 1-mediated lung inflammation and autoimmune encephalomyelitis [44], suggesting B7-H3’s role as a negative regulator of T helper type 1 responses.”
BackgroundImmune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma
Luo, Y., Yang, Y., Shen, C., Ma, B., Xu, W., Wang, Q., Zhang, Y., Liao, T., Wei, W., & Wang, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.859013 · Cited by 36
“B7H3 is involved in the inhibition of T cells, is overexpressed in a wide spectrum of tumor tissues, and is linked to disease states and prognosis (42, 43).”
BackgroundPBK phosphorylates MSL1 to elicit epigenetic modulation of CD276 in nasopharyngeal carcinoma
Wang, M.-Y., Qi, B., Wang, F., Lin, Z.-R., Li, M., Yin, W., Zhu, Y.-Y., He, L., Yu, Y., Yang, F., et al. (2021) · Oncogenesis · doi:10.1038/s41389-020-00293-9 · Cited by 35
B7x in the Periphery Abrogates Pancreas-Specific Damage Mediated by Self-reactive CD8 T Cells
Lee, J. S., Scandiuzzi, L., Ray, A., Wei, J., Hofmeyer, K. A., Abadi, Y. M., Loke, P., Lin, J., Yuan, J. D., SERREZE, D. V., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201241 · Cited by 34
Saatian, B., Yu, X.-Y., Lane, A. P., Doyle, T., Casolaro, V., & Spannhake, E. W. (2004) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00132.2003 · Cited by 35
“Recent studies have proposed a downregulatory function for B7-H3 (37, 38) and expanded the potential role of this ligand in antitumor immunity (39).”
Erratum: Recent Advances in Dendritic Cell Biology
Adams, S., O’Neill, D. W., & Bhardwaj, N. (2005) · Journal of Clinical Immunology · doi:10.1007/s10875-005-4086-2 · Cited by 52
“B7-H3 and B7x are broadly expressed on many cell types and may be involved in attenuation of inflammatory responses in peripheral tissues (52, 53).”
Meci, A., Goyal, N., & Slonimsky, G. (2024) · Cancers · doi:10.3390/cancers16040703 · Cited by 39
“B7H3 is found on cytotoxic and helper T cells and it has been posited to negatively regulate T cell function [123].”
BackgroundFacts and Hopes on Cancer Immunotherapy for Small Cell Lung Cancer
Zugazagoitia, J., Charris, H. R. O., Baena, J., Ucero, A. C., & Paz-Ares, L. G. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1159 · Cited by 39
Durlanik, S., Fundel‐Clemens, K., Viollet, C., Huber, H. J., Lenter, M., Kitt, K., & Pflanz, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-94360-9 · Cited by 34
Brustmann, H., Igaz, M., Eder, C., & Brunner, A. H. (2015) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000116 · Cited by 33
“However, B7-H3 has been shown to inhibit CD4 and CD8 T-cell proliferation and interferon-g production by anti-CD3 and to impair Type 1 T-helper cell responses (6,26).”
BackgroundB7-H3 Contributes to the Development of Pathogenic Th2 Cells in a Murine Model of Asthma
Nagashima, O., Harada, N., Usui, Y., Yamazaki, T., Yagita∥, H., Okumura, K., Takahashi, K., & Akiba, H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.6.4062 · Cited by 34
Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells.
Loke, P., & Allison, J. P. (2004) · Arthritis Research · doi:10.1186/ar1225 · Cited by 37
“Th1 responses, the B7-H3-deficient mice have an enhanced interferon-γ response in airway inflammation experiments, suggesting an inhibitory role [32].”
BackgroundPrognostic significance of B7-H3 expression in patients with colorectal cancer: A meta-analysis
Fan, H., Zhu, J., & Yao, X. (2016) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.326.11511 · Cited by 31
Roles of B7-H3 in Cervical Cancer and Its Prognostic Value
Han, S., Shi, X., Liu, L., Zong, L., Zhang, J., Chen, Q., Qian, Q., Chen, L., Wang, Y., Jin, J., et al. (2018) · Journal of Cancer · doi:10.7150/jca.24959 · Cited by 31
“combine with T cell receptors in the blood, which would provide inhibitory signals[29-32].”
BackgroundLi, P., Yang, Y., Jin, Y., Zhao, R. Z., Dong, C., Zheng, W., Zhang, T., Li, J., & Gu, Z. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2017-x · Cited by 31
Abu-Shahba, N., Mahmoud, M., El-Erian, A. M., Husseiny, M. I., Eldeen, G. N., Helwa, I., Amr, K. S., ElHefnawi, M., Othman, A. I., Ibrahim, S., et al. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.106072 · Cited by 33
Therapeutic opportunities in the B7/CD28 family of ligands and receptors
Carreno, B. M., Carter, L., & Collins, M. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.02.003 · Cited by 32
The Role of Mononuclear Phagocytes in the Testes and Epididymis
Shi, X., Zhao, H., Kang, Y., Dong, X., Yu, C., Xie, Q., Duan, Y., Liao, A., & Huang, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010053 · Cited by 36
“However, subsequent studies have shown that B7-H3 also has the function of mediating the negative regulation of T cells in vitro and in vivo [96,97].”
BackgroundMelanoma: oncogenic drivers and the immune system.
Karachaliou, N., Pilotto, S., Teixidó, C., Viteri, S., González‐Cao, M., Riso, A. A., Morales-Espinosa, D., Molina‐Vila, M. Á., CHAIB-OUKADOUR, I., Santarpía, M., et al. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.08.06 · Cited by 34
“B7-H3 is a transmembrane protein, expressed on immune and non-immune cells, able to both up- and down-modulate T cells activation (219,220).”
BackgroundAmori, G., Sugawara, E., Shigematsu, Y., Akiya, M., Kunieda, J., Yuasa, T., Yamamoto, S., Yonese, J., Takeuchi, K., & Inamura, K. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00331-6 · Cited by 32
B7-H3-targeted CAR-T cell therapy for solid tumors
Li, G., Wang, H., Wu, H., & Chen, J. (2022) · International Reviews of Immunology · doi:10.1080/08830185.2022.2102619 · Cited by 38
“acid identity with other B7 family ligands [1].”
BackgroundHarnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy
Yu, L., Sun, M., Zhang, Q., Zhou, Q., & Wang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.982026 · Cited by 33
B7-H3 silencing inhibits tumor progression of mantle cell lymphoma and enhances chemosensitivity
Zhang, W., Wang, Y., Wang, J., Dong, F., Zhu, M., Wan, W., Li, H.-S., Wu, F., Yan, X., & Ke, X. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2962 · Cited by 31
Downregulated miR‐187 contributes to the keratinocytes hyperproliferation in psoriasis
Tang, L., He, S., Zhu, Y., Feng, B., Su, Z., Liu, B., Xu, F., Wang, X., Liu, H., Li, C., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27135 · Cited by 29
“Previous studies indicated that CD276 plays a controversial (Seaman et al., 2017; Suh et al., 2003) role in the adaptive immune response.”
BackgroundInfluentialInteraction of Regulatory T Cells with Antigen-Presenting Cells in Health and Disease
Mahnke, K., Ring, S., Bedke, T., Karakhanova, S., & Enk, A. (2008) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000154854 · Cited by 32
Peptides of CD200 Modulate LPS-Induced TNF-α Induction and Mortality In Vivo
Gorczynski, R., Boudakov, I., & Khatri, I. A. (2007) · Journal of Surgical Research · doi:10.1016/j.jss.2007.04.043 · Cited by 31
“Among the well-defined stimulatory molecules are CD28, CD154, CTLA 4-1BBL, and CD134 [1–5], while molecules contribu ing to negative signaling to T cells include PD-1 B7-H3 [6–8].”
BackgroundMurine B7-H3 Is a Co-Stimulatory Molecule for T Cell Activation
Yan, R., Yang, S. F., Gu, A., Zhan, F., He, C., Qin, C., Zhang, X., & Feng, P. (2013) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2013.0052 · Cited by 29
Zhang, G., Chen, Y., Shi, Q., Ma, H.-B., Ge, Y., Wang, Q., Jiang, Z., Xu, Y., & Zhang, X. (2004) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/36.6.430 · Cited by 29
Immune checkpoint blockade therapy for bladder cancer treatment
Kim, J. (2016) · Korean journal of urology · doi:10.4111/icu.2016.57.s1.s98 · Cited by 30
“These immune regulators include LAG-3 (lymphocyteactivation gene 3) [43,44], TIM-3 (T-cell immunoglobulin and mucin containing protein-3) [45,46], B7-H3 (B7 homolog 4, B7S1, B7x, VTCN1) [41,47,48] and B7-H4/B7-Hx (V domain Ig suppressor of T-cell activation, B7-H5 or PD-1 S102 www.icurology.org http://dx.doi.org/10.41…”
BackgroundInfluentialB7-H3 in Cancer Immunotherapy—Prospects and Challenges: A Review of the Literature
Mielcarska, S., Kot, A., Dawidowicz, M., Kula, A., Sobków, P., Kłaczka, D., Waniczek, D., & Świętochowska, E. (2025) · Cells · doi:10.3390/cells14151209 · Cited by 34
“Furthermore, B7-H3 has been shown to negatively regulate Th1 responses, with its expression in dendritic cells being notably enhanced by interferon-γ (a Th1-associated cytokine) and diminished by interleukin-4 (IL-4), a Th2 cytokine [28].”
miRNAs as Key Players in the Management of Cutaneous Melanoma
Lorusso, C., Summa, S. D., Pinto, R., Danza, K., & Tommasi, S. (2020) · Cells · doi:10.3390/cells9020415 · Cited by 31
“Recently, B7-H3 has been proposed as an immune inhibitory protein due to its role in the inhibition of T cell proliferation [51,52].”
BackgroundB7-H3, Negatively Regulated by miR-128, Promotes Colorectal Cancer Cell Proliferation and Migration
Hu, X., Xu, M., Hu, Y., Li, N., & Zhou, L. (2021) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-021-00975-0 · Cited by 28
B7-H3 in Pediatric Tumors: Far beyond Neuroblastoma
Bottino, C., Vitale, C., Dondero, A., & Castriconi, R. (2023) · Cancers · doi:10.3390/cancers15133279 · Cited by 29
“The study published in 2004 also demonstrated the immunomodulatory role of B7-H3 in humans, in line with what was described in mice [5,6].”
ResultB7-H3: A promising therapeutic target for autoimmune diseases
Chen, Y., Guan, S., Deng, J., Yang, H., Xu, W., Xu, S., Shao, M., Gao, X., Xu, S., Shuai, Z., et al. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104077 · Cited by 28
Metadata
- Authors
- Suh, W.-K., Gajewska, B. U., Okada, H., Gronski, M. A., Bertram, E. M., Dawicki, W., Duncan, G. S., Bukczynski, J., Plyte, S., Elia, A., Wakeham, A., Itie, A., Chung, S., Da Costa, J., Arya, S., Horan, T., Campbell, P., Gaida, K., Ohashi, P. S., Watts, T. H., Yoshinaga, S. K., Bray, M. R., Jordana, M., & Mak, T. W.
- Affiliations
- University of Toronto (CA)
- McMaster University (CA)
- Amgen (United States) (US)
- Corresponding author
- Suh, Woong-Kyung
- Mak, Tak W
- ORCID
- Venue
- Nature Immunology
- Published
- 2003-08-17
- Volume
- 4
- Issue
- 9
- Pages
- 899-906
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W2052644931
- Cited by
- 576
- References
- 47
- Citations by year
- 2026: 17 · 2025: 39 · 2024: 32 · 2023: 30 · 2022: 37 · 2021: 48 · 2020: 35 · 2019: 29 · 2018: 12 · 2017: 21 · 2016: 20 · 2015: 25 · 2014: 9 · 2013: 18 · 2012: 29
- FWCI
- 7.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- B7-H3, B7 family, T cell proliferation, airway inflammation, interferon-gamma, IL-4, dendritic cells, experimental autoimmune encephalomyelitis, negative regulation of immune response, gene targeting
- MeSH terms
- Animals, Autoantibodies, Dendritic Cells, Encephalomyelitis, Autoimmune, Experimental, Flow Cytometry, Interferon-gamma, Lymphocyte Activation, Lymphocytic choriomeningitis virus, Mice, Inbred C57BL, Orthomyxoviridae, Receptors, Antigen, T-Cell, Vesicular stomatitis Indiana virus, Down-Regulation, Interleukin-4, B7-1 Antigen, Mice, Knockout, Th1 Cells, Mice, B7 Antigens
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.